Please assess the completion status of the following clinical trial:

Trial Title: Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Participated in Study 20110233 (NCT01588496) or another qualifying evolocumab parent protocol and have a diagnosis of familial hypercholesterolemia.~OR~* Have a diagnosis of familial hypercholesterolemia AND~* Males and females ≥ 12 to ≤ 80 years of age~* Stable low-fat diet and lipid-lowering therapies for at least 4 weeks~* Low-density lipoprotein cholesterol (LDL-C) \>= 130 mg/dl (3.4 mmol/L) for subjects without diagnosed coronary heart disease (CHD)/CHD risk equivalent OR LDL-C \>= 100 mg/dl (2.6 mmol/L) for subjects with diagnosed CHD or CHD risk equivalent OR apheresis patients have no LDL-C entry requirement~* Fasting triglycerides ≤ 400 mg/dL(4.5 mmol/L)~* Body weight of \> 40 kg or greater at screening for subjects less than 18 years of age~Exclusion Criteria:~* New York Heart Failure Association (NYHA) class III or IV or last known left ventricular ejection fraction \< 30%~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of screening~* Planned cardiac surgery or revascularization~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).